# Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600.

> **NCT03929510** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 6 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** 14C-PF-06651600
- **DRUG:** 14C-PF-06651600 IV
- **DRUG:** PF-06651600

## Key facts

- **NCT ID:** NCT03929510
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-23
- **Primary completion:** 2019-07-05
- **Final completion:** 2019-07-05
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03929510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03929510, "Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03929510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*